161 related articles for article (PubMed ID: 23773070)
1. Caspase-6 as a novel early target in the treatment of Alzheimer's disease.
LeBlanc AC
Eur J Neurosci; 2013 Jun; 37(12):2005-18. PubMed ID: 23773070
[TBL] [Abstract][Full Text] [Related]
2. Activation of caspase-6 in aging and mild cognitive impairment.
Albrecht S; Bourdeau M; Bennett D; Mufson EJ; Bhattacharjee M; LeBlanc AC
Am J Pathol; 2007 Apr; 170(4):1200-9. PubMed ID: 17392160
[TBL] [Abstract][Full Text] [Related]
3. Increased Caspase-6 activity in the human anterior olfactory nuclei of the olfactory bulb is associated with cognitive impairment.
Foveau B; Albrecht S; Bennett DA; Correa JA; LeBlanc AC
Acta Neuropathol Commun; 2016 Dec; 4(1):127. PubMed ID: 27931265
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease and amyloid: culprit or coincidence?
Skaper SD
Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
[TBL] [Abstract][Full Text] [Related]
5. Viewpoint: Crosstalks between neurofibrillary tangles and amyloid plaque formation.
Luan K; Rosales JL; Lee KY
Ageing Res Rev; 2013 Jan; 12(1):174-81. PubMed ID: 22728532
[TBL] [Abstract][Full Text] [Related]
6. Familial amyloid precursor protein mutants cause caspase-6-dependent but amyloid β-peptide-independent neuronal degeneration in primary human neuron cultures.
Sivananthan SN; Lee AW; Goodyer CG; LeBlanc AC
Cell Death Dis; 2010 Nov; 1(11):e100. PubMed ID: 21368865
[TBL] [Abstract][Full Text] [Related]
7. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.
Walton JR
J Inorg Biochem; 2007 Sep; 101(9):1275-84. PubMed ID: 17662457
[TBL] [Abstract][Full Text] [Related]
8. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.
Barage SH; Sonawane KD
Neuropeptides; 2015 Aug; 52():1-18. PubMed ID: 26149638
[TBL] [Abstract][Full Text] [Related]
9. Caspase-mediated degeneration in Alzheimer's disease.
Cribbs DH; Poon WW; Rissman RA; Blurton-Jones M
Am J Pathol; 2004 Aug; 165(2):353-5. PubMed ID: 15277211
[No Abstract] [Full Text] [Related]
10. Fyn, a potential target for Alzheimer's disease.
Yang K; Belrose J; Trepanier CH; Lei G; Jackson MF; MacDonald JF
J Alzheimers Dis; 2011; 27(2):243-52. PubMed ID: 21799250
[TBL] [Abstract][Full Text] [Related]
11. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
12. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review).
Cai Z
Mol Med Rep; 2014 May; 9(5):1533-41. PubMed ID: 24626484
[TBL] [Abstract][Full Text] [Related]
13. The cholinergic system in aging and neuronal degeneration.
Schliebs R; Arendt T
Behav Brain Res; 2011 Aug; 221(2):555-63. PubMed ID: 21145918
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease: cholesterol a menace?
Mathew A; Yoshida Y; Maekawa T; Kumar DS
Brain Res Bull; 2011 Aug; 86(1-2):1-12. PubMed ID: 21741455
[TBL] [Abstract][Full Text] [Related]
15. Caspase-6-cleaved Tau fails to induce Tau hyperphosphorylation and aggregation, neurodegeneration, glial inflammation, and cognitive deficits.
Noël A; Foveau B; LeBlanc AC
Cell Death Dis; 2021 Mar; 12(3):227. PubMed ID: 33649324
[TBL] [Abstract][Full Text] [Related]
16. Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex.
van de Nes JA; Nafe R; Schlote W
Brain Res; 2008 Jun; 1213():152-65. PubMed ID: 18455153
[TBL] [Abstract][Full Text] [Related]
17. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
[TBL] [Abstract][Full Text] [Related]
18. The role of caspase cleavage of tau in Alzheimer disease neuropathology.
Cotman CW; Poon WW; Rissman RA; Blurton-Jones M
J Neuropathol Exp Neurol; 2005 Feb; 64(2):104-12. PubMed ID: 15751224
[TBL] [Abstract][Full Text] [Related]
19. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].
Kuzuhara S
Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870
[TBL] [Abstract][Full Text] [Related]
20. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models.
Zhang Q; Zhang X; Sun A
Acta Neuropathol; 2009 Jun; 117(6):687-97. PubMed ID: 19190923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
